American Healthcare REIT: Real Estate Cash Engine With a Heavy Refinancing Footprint

The Quarter in Context

American Healthcare REIT's second quarter ended June 30, 2026, with resident fees and services revenue of $634,519,000, up roughly 26.6% from $501,285,000 in the year-ago quarter, on total revenue of $674,250,000. Total expenses of $631,813,000, including property operating expenses of $524,838,000 and depreciation and amortization of $72,125,000, left operating income of $137,239,000 and net income attributable to controlling interest of $30,606,000. Diluted earnings per share were $0.16 versus $0.06 a year earlier, and operating cash flow for the quarter was $118,620,000, with the trailing twelve months reaching $362,037,000.

The comparison must be read carefully. Resident fees and services revenue is recognized through RIDEA-structured operating property subsidiaries, where revenue and large property-level operating expenses both flow through the income statement. The acquisition activity is heavy: $291.7 million of real estate acquisitions and $86.0 million of development and capital expenditures in the first six months of 2026, against only $7.3 million of disposition proceeds. The portfolio therefore grew meaningfully, but cash earnings power will depend on how those new assets ramp. The disclosed weighted-average effective interest rate on debt was 4.23% as of June 30, 2026. Subsequent-event disclosure notes an additional $1.041 billion of senior-housing acquisitions completed after quarter end.

Business Model and Profit Engine

American Healthcare REIT is a self-managed healthcare REIT that owns and operates clinical real estate through four reportable segments: integrated senior health campuses (ISHC), senior housing operating properties (SHOP), outpatient medical (OM), and triple-net leased properties. The principal revenue engines by segment are resident fees and services from ISHC and SHOP, rental income from OM, and contractual rent from triple-net tenants. Resident fees and services revenue is the dominant engine, accounting for the bulk of consolidated revenue and split between ISHC (about 81% of resident fees in Q2 2026) and SHOP (about 19%). Real estate revenue from OM and triple-net assets contributed a smaller slice, with OM revenue meaningfully larger than triple-net lease income. The company serves two broad customer classes: (a) individual residents of ISHC and SHOP properties, who pay for housing, assisted living, and skilled nursing services, and (b) institutional tenants of OM and triple-net buildings, who pay contractual rent. Within the resident base, payor mix is genuinely diversified across private payors, Medicare, Medicaid, and Medicare Advantage, with private payors leading and Medicaid a meaningful contributor in ISHC.

What customers buy is accordingly different by segment. Residents of ISHC and SHOP buy a recurring service relationship: housing bundled with assisted living, memory care, or skilled nursing, billed monthly in advance for private payers and at contractually agreed daily rates for government payers. OM and triple-net tenants buy access to a specialized medical building under a multi-year lease, with rent recognized straight-line over the term. Revenue is recognized as services are rendered for resident fees and over time for leases, so occupancy, mix of payors, and rate increases directly drive the top line. The model has heavy operating leverage: in Q2 2026, property operating expenses were $524.8 million against $634.5 million of resident fees, leaving a thin segment-level margin that is highly sensitive to staffing costs, occupancy mix, and reimbursement rates. Operating income rose from $103.2 million to $137.2 million year over year, but the improvement was aided by acquisition volume rather than a demonstrated lift in unit economics; depreciation and amortization alone consumed $72.1 million.

Observable conditions that would weaken the profit engine include a sustained drop in private-pay occupancy (which carries the highest rate), Medicare or Medicaid reimbursement compression, an inability to staff properties (a chronic industry risk for SNFs and SHOP), a sharp rise in labor costs at the property level, and higher interest expense on the $550 million variable-rate line of credit that is fully swapped today against one-month movements but will face refinancing risk when the facility matures in 2027. Customer concentration is diffuse across many individual residents and a few large healthcare tenants at the OM/triple-net level, but the segment is exposed to systemic reimbursement and demographic shifts rather than a single tenant default.

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing; they are calculations from SEC facts rather than separately reported quarterly line items. Quality is mixed. Reported GAAP net income swung from a loss of $31.8 million in 2024 to a small positive $10.8 million in 2025 and to a clearly positive $54.3 million in the first six months of 2026. Diluted EPS for the trailing twelve months totaled $0.68, while a single quarter cannot establish a sustainable run rate. Non-cash and non-recurring items materially affect reported net income: depreciation and amortization of $139.2 million in the first half of 2026, impairment charges of $2.1 million, and a $5.6 million gain on real estate dispositions. The fair-value swing on derivatives added back $1.9 million of non-cash income, and stock-based compensation absorbed $10.6 million. These adjustments push reported GAAP earnings below NAREIT FFO, which totaled $188.3 million in the first six months and $98.0 million in Q2 alone, with Normalized FFO reaching $105.2 million for the quarter.

Cash conversion in the first half of 2026 was reasonable: operating cash flow of $199.7 million versus net income of $55.0 million reflects normal add-back of $139.2 million in D&A. Working capital was a mild drag, with receivables rising by $25.9 million. The big swing factor is capital intensity. Financing available $216.7 million, principally from $420.8 million of stock issuance proceeds (net of $4.0 million of offering costs recognized in equity and $3.5 million of payments to taxing authorities shown in financing) against $94.4 million of distributions paid. Mortgage principal repayments of $95.5 million reduced leverage. Because total capex is not separately disclosed in the financial package (the capital expenditure metric has no same-unit fact within the freshness window, and the package flags this gap), the difference between operating cash flow and a free-cash-flow proxy cannot be computed with confidence. Author inference: the cash flow statement's "developments and capital expenditures" line of $86.0 million for the first half of 2026 likely blends maintenance and growth spending, but the filing does not separate them.

Business Quality, Moat, and Industry Position

American Healthcare REIT has scale advantages that are visible in the filings: a portfolio of 347 buildings and integrated senior health campuses representing approximately 23.34 million square feet as of June 30, 2026, with an aggregate contract purchase price of $5.73 billion. Geographic and asset-type diversification across ISHC, SHOP, OM, and triple-net reduces single-market concentration, and the RIDEA structure allows the company to capture both rental and operating economics on its senior-housing assets. The triple-net portfolio provides more stable, contractually defined rent that partially offsets the operating volatility of the RIDEA-managed assets.

The moat, however, is moderate rather than fortress-like. Healthcare real estate is capital-intensive but not uniquely protected; skilled-nursing and senior-housing supply is regulated in many states through certificates of need, which provides a barrier to new construction. The company's RIDEA structure and integrated management platform (about 121 employees as of December 31, 2025) give it operating expertise that smaller operators lack, and Medicare/Medicaid scale creates some negotiating leverage with payors. On the other hand, the OM segment competes against a fragmented outpatient-medical real estate market where RPT, Healthcare Realty, and private buyers are active; the SHOP segment faces new supply in some markets despite the broader narrative of low supply. Payor concentration risk is meaningful because Medicare and Medicaid reimbursements are set administratively and can shift between rule cycles. Customer concentration is largely diffuse across individual residents rather than a single tenant, but the segment is exposed to systemic reimbursement and demographic shifts.

The supply-chain question is whether AHR is a bottleneck or an important participant. Healthcare real estate supply is constrained in many geographies by certificate-of-need regulation and zoning, but AHR itself is one buyer among several competing for high-quality facilities and skilled operating partners. The RIDEA operating model lets the company capture both real estate rent and operating margin, which strengthens its competitive position, but it also adds labor and regulatory risk. Overall, AHR sits at an important-participant level: an important participant with scale but not a uniquely protected position, and not a core bottleneck of the healthcare delivery value chain.

Management and Capital Allocation

Jeffrey T. Hanson serves as Chairman of the Board and Chief Executive Officer (and is identified as Interim Chief Executive Officer in the 2025 Annual Report). Brian S. Peay is Chief Financial Officer. The 2025 Annual Report on Form 10-K was signed on February 27, 2026, and management certification confirmed effective disclosure controls as of June 30, 2026. The CEO's principal affiliated entity, AHI Group Holdings, LLC, owns part of the operating partnership's limited-partner units, which creates an incentive alignment for the founders but also ties insider economics to dividend continuation and per-share growth.

Capital allocation in the first half of 2026 leaned heavily into growth and refinancing. The company spent $291.7 million on real estate acquisitions and $86.0 million on developments and capital expenditures, raised $420.8 million of equity (gross) through an at-the-market or follow-on program, paid $94.4 million in distributions, and repaid $95.5 million of mortgage principal while leaving the $550 million line of credit and term loan unchanged. The board authorized a $0.25 per share quarterly distribution ($1.00 annualized), and the filing notes that some portion of the distribution may have been paid from borrowings when current and accumulated earnings and profits were insufficient. The company is in compliance with debt covenants as of June 30, 2026. No share repurchases occurred in the period under the public repurchase program; the only share "buyback" activity was a small withholding of 27,179 shares in April 2026 to satisfy employee tax withholding at a $48.28 weighted-average price, which is not a capital-return signal.

Valuation and What the Market Already Expects

The dated market snapshot shows AHR closing at $55.385 on August 3, 2026, with a market capitalization of approximately $10.67 billion. The filing discloses 194,689,026 common shares issued and outstanding as of June 30, 2026, and 217,998,775 shares outstanding as of August 3, 2026, which is materially higher than the diluted weighted-average count and reflects later issuance. The dated market capitalization from the Nasdaq snapshot is treated as the authoritative figure, and that capitalization implies the market is pricing AHR at roughly 22 times trailing-twelve-month operating income of $480.1 million and at roughly 29 times trailing-twelve-month operating cash flow of $362.0 million. A same-date current-debt and long-term-debt pair is not available in the available SEC data, so no current net-cash or net-debt adjustment is used; the enterprise-value bridge is therefore qualitative. On trailing-twelve-month operating cash flow of $362 million, the equity capitalization of $10.67 billion represents a roughly 3.4% cash-flow yield on cash flow before debt service and reinvestment; a forward-looking yield after dividends of $178.5 million paid over the trailing twelve months would be far lower and would require steadily rising operating cash flow to support the current price. Diluted weighted-average shares expanded roughly 20% year over year, so per-share growth in cash flow has been dampened even as total cash flow grew. The reverse-DCF qualitative read is that the market is pricing in either (i) sustained acceleration in NOI per property, (ii) accretive acquisitions at attractive spreads to cost of capital, or (iii) some combination of both. A normalized FCF figure cannot be reliably computed from the available SEC data because the company has not disclosed a clean capex number within the freshness window, and the operating cash flow series mixes reporting conventions (six-month cumulative for Q2 versus three-month for Q1). The filing does not provide a forward management projection, so any year-five/year-ten normalization case should label revenue base, FCF margin, FCF dollar value, and yield convention as assumptions rather than as audited facts.

The most important valuation signal is the divergence between GAAP net income (TTM roughly $121 million) and NAREIT FFO (six-month FFO of $188 million, of which approximately $98 million is attributable to Q2 alone). The market is clearly pricing on FFO rather than GAAP earnings, which is conventional for REITs, but it raises the bar on operating discipline. A roughly 20x FFO multiple is not a defensive multiple for a capital-intensive REIT whose $890 million of mortgage debt at a 3.84% weighted average rate (per the maturity table) and $550 million of variable-rate revolver debt will need refinancing in coming years.

Ten-Year Cash Flow to Fair Market Value

Direct compounding from a current free-cash-flow proxy is invalid for this issuer because the available SEC data does not disclose a clean trailing free-cash-flow figure, the operating cash flow series mixes cumulative and quarterly conventions, and total capital expenditure is missing as a same-unit fact within the freshness window. A traditional dividend-discount or FCF-yield approach is therefore not reproducible from the available evidence in a single deterministic table, so the discussion below lays out author assumptions for bear/base/bull normalization paths rather than a single audited value.

Bear path (author assumption): revenue base of $2.34 billion in TTM, growing 4% annually to about $3.03 billion at year five and $3.70 billion at year ten, with operating income margin compressed back to roughly 16% by year five from the current 21.6% and FCF margin of 6%, yielding year-five FCF of roughly $182 million and year-ten FCF of roughly $222 million. Discounted at a 10% required return, the implied equity value is well below the dated $10.7 billion market capitalization. Base path (author assumption): revenue grows 6% annually to $3.14 billion at year five and $4.21 billion at year ten, FCF margin holds at 9%, yielding year-five FCF of roughly $282 million and year-ten FCF of roughly $379 million. Bull path (author assumption): revenue grows 9% annually to $3.62 billion at year five and $5.59 billion at year ten, FCF margin expands to 12% by year ten, yielding year-five FCF of roughly $390 million and year-ten FCF of roughly $670 million.

The author reiterates that no audited fair value is claimed in this section; the figures above are author assumptions to bracket the question of what cash-flow normalization the dated price implies. The qualitative read is that even the bull path requires both continued equity issuance (which the trailing record confirms is occurring, with $420.8 million raised in H1 2026 alone) and an FFO yield compression that the dated price already prices in.

Five Value-Investing Lenses

Benjamin Graham Lens

Graham would test balance-sheet resilience first. AHR carries $890.1 million of fixed-rate mortgage debt plus a $550 million line of credit and term loan, with a weighted-average effective rate of 4.23% as of June 30, 2026. Unrestricted cash of $156.9 million covers roughly three quarters of distributions at the current run rate but covers only a fraction of total debt. Stockholders' equity of $3.69 billion carries accumulated deficit of $1.60 billion, reflecting years of impairment charges and shareholder distributions that exceeded cumulative earnings. The company is in compliance with debt covenants but discloses that some distributions may be paid from borrowings. Graham would likely view the equity as too dependent on continued equity issuance ($420.8 million raised in H1 2026) to qualify as a defensive investment at the dated price, regardless of how profitable operations appear on a cash basis.

Benjamin Franklin Lens

Franklin's thrift and discipline lens focuses on opportunity cost and capital preservation. The $94.4 million of distributions paid in the first half of 2026 against $199.7 million of operating cash flow means distributions consume 47% of operating cash flow before any reinvestment. Capital expenditures and acquisitions of $377.8 million in the first half cannot be funded from operations alone, requiring either asset sales or equity issuance. The Franklin lens asks whether the retained capital earns a satisfactory return: the company spent $291.7 million on acquisitions and $86.0 million on developments, with the filing showing $5.73 billion of total contracted purchase price. Whether the recent $1.04 billion of post-quarter-end SHOP acquisitions clear a hurdle above the 4.23% blended cost of debt depends on property-level NOI yield, which is not separately disclosed. Until that hurdle is verified, the disciplined reader would treat this as an open question.

Warren Buffett Lens

Buffett would focus on owner economics, capital allocation, and the integrity of management's incentive structure. Normalized FFO of $105.2 million for Q2 2026 and $200.0 million for H1 2026 represents the cleanest read on recurring cash earnings, but a substantial portion comes from recently acquired properties whose full-year contribution is not yet visible. Buffett would note that the $420.8 million of equity issuance in H1 2026 dilutes existing holders by 4.7% on a share-count basis at the dated price; over the trailing twelve months, diluted weighted-average shares grew from 161.1 million to 193.3 million, a 20% expansion. This is a high-cost capital strategy in a sector where REITs historically compounded through both acquisition growth and stable share count. Buffett would likely wait for evidence that the capital raised is being deployed at attractive spreads before committing.

Charlie Munger Lens

Munger would invert the question: what would break this thesis? Three observable indicators would force a downgrade: (i) a sustained decline in private-pay occupancy at ISHC, which carries the highest rate and supports roughly half of resident fees; (ii) a credit-rating downgrade on the variable-rate revolver, which would raise the cost of refinancing the $550 million line of credit maturing in 2027; and (iii) a sharp rise in labor costs at the SHOP and ISHC properties, which would compress property operating margins below the current 82.7% of resident fees. Munger would also challenge the management thesis that RIDEA structure creates durable value: the company's $1.6 billion accumulated deficit is a direct consequence of years of dividends and impairments outpacing retained earnings, and that history should give any reader pause.

Li Lu Lens

Li Lu would test the circle-of-competence question first. Healthcare real estate is a specific, regulated subsector where local market knowledge matters; the company operates across the United States, the United Kingdom, and the Isle of Man, which stretches any operator's circle. The 121-employee integrated platform is a meaningful but small management footprint for a $5.73 billion portfolio. Culture, to the extent it is observable in the filings, reflects the founders' long-horizon orientation through continuous equity issuance and selective development, but the absence of share repurchases and the persistent reliance on at-market equity raises the question of whether management is compounding per-share value or simply growing the asset base. The circle-of-competence test fails on the margin: a careful reader would want more property-level disclosure (occupancy, rate growth, same-store NOI by segment) before making a long-term commitment.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

The most important risks are refinancing, reimbursement, and acquisition integration. The $550 million variable-rate line of credit matures in 2027, and the mortgage portfolio has scheduled maturities of $64.2 million in 2026, $56.2 million in 2027, and $139.7 million in 2028. A 100-basis-point rise in interest rates on unhedged future debt would meaningfully compress distributable cash flow. Reimbursement risk runs through Medicare and Medicaid, which together account for a substantial portion of ISHC and SHOP revenue: Medicaid represented $231.1 million of H1 2026 resident fees and Medicare $285.6 million. Any reduction in these rates would directly hit the largest segment.

Three observable thesis breakers would force a downgrade: (1) a sustained drop in private-pay occupancy at ISHC below disclosed prior-year levels, since private payors carry the highest rate and the segment contributes the majority of resident fees; (2) a credit-rating action or covenant amendment on the credit facility or mortgage portfolio, indicating market concern about leverage and refinancing capacity; (3) a sharp deterioration in same-store NOI growth across the SHOP and OM segments, which would mean new acquisitions are not generating the FFO growth the market is paying for. The most likely wrong assumption is that the recent surge in revenue and operating income (which grew 33% year over year in Q2 2026) is sustainable on a per-share basis given the 20% trailing share-count expansion.

The biggest data gap is segment-level profitability for OM and triple-net leased properties, which is not separately disclosed in the condensed quarterly filing. The second gap is a clean trailing free-cash-flow figure, which the available SEC data flags as missing because capital expenditure data has no same-unit fact within the freshness window. The third gap is the actual yield on the $1.04 billion of post-quarter-end SHOP acquisitions; without that disclosure, the reader cannot judge whether the $420.8 million of H1 2026 equity issuance is being deployed at attractive spreads.

Investment Conclusion

American Healthcare REIT is a high-quality operator with a recognizable moat in RIDEA-structured senior-housing real estate, but the dated $10.67 billion market capitalization does not provide a clear margin of safety given the heavy capital intensity, the 20% trailing share-count expansion, and the reliance on continued equity issuance to fund acquisitions and dividends. Operating cash flow of $362 million over the trailing twelve months and trailing-twelve-month operating income of $480 million support the current price only under assumptions of sustained FFO growth that the filings do not yet confirm. The conclusion is that AHR is a name worth watching but not yet fairly valued at the dated price, and any commitment should be conditional on either a meaningful pullback in share price or evidence that recently deployed capital is producing same-store NOI growth above the 4.23% blended cost of debt.

This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. All figures are derived from publicly filed SEC documents and the dated market snapshot from Nasdaq; readers should consult the original filings and conduct their own due diligence before making any investment decision.